Symbiosis Pharmaceutical Services has expanded its quality control (QC) laboratory with the installation of a new 30 Degree C stability chamber, enhancing its ability to support global drug development and commercial supply.

The addition allows the company to replicate all four climatic zones defined under ICH Q1A(R2) guidelines, enabling comprehensive stability testing of drug products across different environmental conditions. This development strengthens Symbiosis’ capability to assess product performance for worldwide distribution, ensuring compliance with regulatory requirements across diverse geographies.

The QC laboratory, commissioned in 2023 and operational since 2024, has played a key role in supporting client programmes by improving in-house analytical capabilities, accelerating data turnaround and streamlining processes from development through to product release.

With the new chamber, Symbiosis now offers a complete range of storage conditions, including  Minus 80 Degree C, Minus 20 Degree C, 5 Degree C, 25 Degree C, 30 Degree C, and 40 Degree C. This full-spectrum capability enhances its ability to conduct robust stability studies for both clinical and commercial drug products.

Commenting on the development, Joanne Anderson, Chief Commercial Officer at Symbiosis, said the expansion marks a significant step in strengthening the company’s commercial drug supply services. She noted that growing global demand for sterile injectable therapies requires advanced testing across varied climatic conditions, and the new capability enables the company to deliver these services under one roof.

The investment reflects Symbiosis’ continued focus on expanding technical infrastructure and offering integrated manufacturing and analytical services. The company specialises in GMP sterile fill-finish manufacturing of injectable biopharmaceuticals and small-molecule drugs, supporting pharmaceutical and biotechnology clients worldwide.